Addiction Medicine Physician in New Bedford, MA at Acadia Healthcare

Date Posted: 3/25/2020

Job Snapshot

Job Description



Part Time Addiction Medicine Physician

Gifford Street Wellness Center

  • Age Group/Range: Adults
  • Practice Setting/Type: Outpatient

Addiction Medicine patients require care from specialty-trained professionals, in a highly-specialized, and quality-focused environment. Our team at Gifford Street Wellness Center in New Bedford, seeking to add a like-minded licensed physician to their diverse and dynamic team.


  • MD license to practice medicine in Ma.
  • DPH controled Subtances registration in Ma
  • DEA certifcate for schedule 2-5 drugs
  • Psychiatrist preferred
  • Board certiied in Adult Psychiatry or Addiction Medicine preferred

Acadia Healthcare's Mission & Vision

Our mission is to create a world-class organization that sets the standard of excellence in the treatment of specialty behavioral health and addiction disorders.

To our clients, we are committed to the creation of behavioral health centers where people receive individualized and quality care that enables them to regain hope in a supportive, caring environment.

To our employees, we are committed to offering an enviable internal culture and environment that encourages and supports both professional and personal growth that you are proud of.

To our customers, we are committed to developing partnerships with physicians, professionals, and payers within the communities we serve through the delivery of high quality specialty behavioral health services at affordable costs while always putting the patient first.

We will strive in all that we do to make Acadia Healthcare synonymous with excellent care, phenomenal customer service and an unparalleled commitment to our patients, staff, physicians, and community.


Physician will in coordination with clinical and management staff:  Provide psychaitric care for substance use disorder pts as well as Complete medical assessments within 48 hours of admission;  Physician will sign all dose orders  Prior to admitting a client into treatment, the licensee shall determine that the client has a current physiologic dependence on opioids of at least a 12-month duration. If the exact term of physiologic dependence cannot be determined, the medical director, or designee, may admit the client to treatment if there is sufficient evidence to reasonably conclude that there was physiologic dependence one year prior to admission. The 12-month duration may be waived if the client:  is pregnant;  is seeking opioid detoxification services;  has been released from a penal institution within the previous six months; or  has been discharged from opioid treatment within the previous two years.  Evidence of Physiologic Opioid Dependence: The licensee shall obtain evidence of physiologic dependence on opioids through reliable methods such as physical examination, laboratory tests and substance use history.  Prior to initiating treatment, the licensee shall under the direction of the Medical Director: o verify that the client with a positive drug screen for methadone is not enrolled in an opioid treatment program; complete an assessment of patient’s current prescription medications prior to prescribing, dispensing or administering an FDA-approved medication for opioid dependence to ensure that the approved medication is not contraindicated bythe patient’s current prescribed medications or health status; o for women of child bearing age, complete a pregnancy test before dispensing or administering or prescribing an FDAapproved medication for opioid dependence; and o review the client's prescription history through the Prescription Monitoring Program (PMP).  Consent to Treatment: The licensee shall ensure that the client voluntarily chooses treatment. The information listed below shall be provided to the client and recorded on a consent form, which shall be signed by the client, and a copy shall be provided to the client. If the client is younger than 18 years old, the consent form shall be signed by the client and the client’s parent or guardian. The information shall also be provided orally: o the nature of FDA-approved medication used in opioid treatment, including benefits and risks, and the benefits and risks of not receiving treatment; o the distinction between detoxification and maintenance and the availability of short-term detoxification treatment for a period not less than 30 days nor more than 180 days; o approximate length of each type of treatment; o a clear statement of the goals of each type of treatment, and the tasks necessary to reach those goals; o need for the client to inform the licensee of current medical conditions and medications the client is currently taking; o acknowledgement that the client may withdraw voluntarily from treatment and discontinue use of medications; o (g) the options available to both the client and the program as a result of either a voluntary or involuntary termination, including medically supervised withdrawal; and o (h) for women of child-bearing age, acknowledgement of the benefits and risks of treatment during pregnancy, and importance of informing the licensee if she is or becomes pregnant.

 (B) Assessment: The licensee shall ensure that the assessment required by 105 CMR 164.072 shall be completed on the first visit. 

(C) Physical Examination: The licensee shall ensure that each client has a physical examination by a physician, or by a qualified healthcare professional under the supervision of a program physician prior to administration of the first dose of medication. The examination shall include: o an assessment of the patient’s substance use disorder; o a brief mental status exam; o tests for the presence of opiates, alcohol, benzodiazepines, cocaine and other drugs of abuse as indicated by the patient’s current substance use history. o an assessment of the possibility of: infectious diseases, including HIV, TB, Viral Hepatitis and sexually transmitted diseases; pulmonary, liver, and cardiac abnormalities; dermatological and neurological sequelae of addiction; and possible concurrent surgical problems. The assessment shall include the following laboratory tests, results of which must be returned no later than 14 days after admission: o tests to determine liver function; o tests to screen for anemia, coronary risk factors; and o complete blood count and differential blood tests.  Dosage: The Medical Director shall ensure that the initial dose of an opioid agonist treatment medication is ordered by a program physician and does not exceed the federal dosage guidelines for the specified opioid;  Documentation: In addition to the requirements of Massachusetts regulation105 CMR 164.083, the medical director, or other authorized health care professional, shall: o ensure that evidence of current physiological dependence is entered in the client record; o ensure that a medical evaluation, including a medical history, is recorded; o ensure that appropriate laboratory results are documented; o ensure that a list of prescription medication, prescribed dosage(s) of all medications, the plan for changing prescribed medications if necessary, including the planned rate of detoxification, when applicable, are documented in the record; o sign or countersign all medical orders; o review and countersign treatment plans at least annually; o ensure that the reasons for any changes in dosage and changes in the permitted number of take-home doses are documented; o attend weekly interdisciplinary team meetings; and o sign telephone orders issued by Physician within 24 hours of giving the order.  Provide supervision as necessary to nurse practitioner practicing at the facility